about
Usefulness of contrast enhanced ultrasound in monitoring therapeutic response after hepatocellular carcinoma treatmentTumor necrosis factor-α inhibitors and chronic hepatitis C: a comprehensive literature reviewBridging and downstaging treatments for hepatocellular carcinoma in patients on the waiting list for liver transplantationAcute hepatitis caused by a natural lipid-lowering product: when "alternative" medicine is no "alternative" at allPercutaneous laser ablation of hepatocellular carcinoma in patients with liver cirrhosis awaiting liver transplantation.Hepatocellular carcinoma treated by conventional transarterial chemoembolization in field-practice: serum sodium predicts survival.Recurrent acute hepatitis associated with use of cetirizine.Ethanol injection is highly effective for hepatocellular carcinoma smaller than 2 cm.Prognostic factors for survival in patients with early-intermediate hepatocellular carcinoma undergoing non-surgical therapy: comparison of Okuda, CLIP, and BCLC staging systems in a single Italian centre.Review article: the hepatic manifestations of hereditary haemorrhagic telangiectasia.Severe veno-occlusive disease after autologous peripheral blood stem cell transplantation for high-grade non-Hodgkin lymphoma: report of a successfully managed case and a literature review of veno-occlusive disease.Management of hepatitis C virus infection recurrence after liver transplantation: an overview.Single-step multimodal locoregional treatment for unresectable hepatocellular carcinoma: balloon-occluded percutaneous radiofrequency thermal ablation (BO-RFA) plus transcatheter arterial chemoembolization (TACE).Portal vein thrombosis and liver transplantation: implications for waiting list period, surgical approach, early and late follow-up.Complete Metabolic Response with Recanalization of Portal Vein Tumor Thrombosis after Sunitinib in a Patient with Advanced Hepatocellular Carcinoma.Long-term maintenance of sustained virological response in liver transplant recipients treated for recurrent hepatitis C.The Italian experience on paediatric liver transplantation: 1988-1999 report.Treatment of hepatitis C recurrence is less successful in female than in male liver transplant recipients.Relationship between gastric localization of hepatitis C virus and mucosa-associated lymphoid tissue in Helicobacter pylori infection.A case of variant angina in a patient under chronic treatment with sorafenib.Is coeliac disease a confounding factor in the diagnosis of NASH?Prevalence, characteristics and severity of non-alcoholic fatty liver disease in patients with chronic plaque psoriasis.Long-term effectiveness of radiofrequency ablation for solitary small hepatocellular carcinoma: a retrospective analysis of 363 patients.Prognostic factors for survival in patients with compensated cirrhosis and small hepatocellular carcinoma after percutaneous ethanol injection therapy.Liver transplantation for Wilson's disease: The burden of neurological and psychiatric disorders.Differentiating hepatocellular carcinoma from dysplastic nodules at gadobenate dimeglumine-enhanced hepatobiliary-phase magnetic resonance imaging.Long-term effectiveness of resection and radiofrequency ablation for single hepatocellular carcinoma ≤3 cm. Results of a multicenter Italian survey.Liver transplantation for hepatitis B virus patients: long-term results of three therapeutic approaches.Ischaemic jejunal vasculitis during treatment with pegylated interferon-alpha 2b and ribavirin for hepatitis C virus related cirrhosis.Early prediction of response to sorafenib in patients with advanced hepatocellular carcinoma: the role of dynamic contrast enhanced ultrasound."Wait and see" policy for early hepatocellular carcinoma.Portal vein tumor thrombosis revascularization during sorafenib treatment for hepatocellular carcinoma.Bridge treatments of hepatocellular carcinoma in cirrhotic patients submitted to liver transplantation.Percutaneous ablation procedures in cirrhotic patients with hepatocellular carcinoma submitted to liver transplantation: Assessment of efficacy at explant analysis and of safety for tumor recurrence.Contrast-enhanced gray-scale harmonic ultrasound in the efficacy assessment of ablation treatments for hepatocellular carcinoma.Acute hepatitis associated with use of paroxetine.Thrombotic risk factors in patients with liver cirrhosis: correlation with MELD scoring system and portal vein thrombosis development.Contrast-enhanced power doppler of the intestinal wall in the evaluation of patients with Crohn disease.Liver transplantation: the Italian experience.Treatment of genotype-1 hepatitis C recurrence after liver transplant improves survival in both sustained responders and relapsers.
P50
Q26799914-7D8FE6D4-26E3-4766-BF56-71588240B92FQ26829390-7ACA0B1F-0372-4680-92A5-B65EEF7B90D3Q26852105-B19FA1ED-C76C-4088-B86A-8F1758B8DD7EQ28242961-5852F4A1-BFD5-458E-AAC0-E3167389AC53Q33426681-B9648F65-4D19-45B5-B846-494ED666E6A9Q33845513-E298419C-C628-4420-8FF9-F0C2431A3654Q34551111-9FE93689-1B08-46F1-B26E-4D55C679F5EEQ35171592-7221899D-2DFB-4CAE-88A4-5D9AE96B6E5FQ35597241-E15DEBCB-6EB8-4882-9981-ADDDBD600B87Q37198016-4FCFA161-7523-4D57-85D9-21DA3831BFADQ37247291-F6171474-593E-4DB5-9B82-56C4B9A1531DQ37844982-C3F058B5-DA46-4164-8C9D-8FB3C2D4814CQ38077466-9B2B63C7-2C0F-4680-8B6C-1CA6254A55C9Q38192256-3F994A49-4152-472E-ADCF-C0BB61DE85CBQ41493315-85D2E6B6-6904-4582-9111-A10B1FB2247EQ42230987-ABD6E43E-DB8F-4A9A-B781-8DCE89CAACA2Q42686846-5BDFA0A4-EB63-4082-AF4B-35FAD7B3A189Q42977889-4CAAA81F-49BA-43B3-BF8C-4620CDD986D7Q43040714-6FF56E22-CE7B-44BA-87A8-FB7A9E785B8FQ43060938-BAC126AC-4370-413B-A4A9-8DC433353616Q43085729-F1400315-6913-4270-97AA-E3C842BB8EF7Q43296041-9CD7B7CB-7E3C-47A1-AA6E-282F24A8FAA5Q43614282-7468B7F8-544E-4BC3-95B3-54A71432FD43Q43666919-733EC021-245F-4FD0-A54A-15EB6EA2EEA0Q43687446-0F118BB5-BCCA-4B44-8E2C-EB7CF64E35CBQ43904191-C68ABB90-CBB4-4649-892D-86544353267DQ44433803-9A6A0B8B-BD12-4BCE-9F9F-F6BB306F21E0Q45392363-0042AA43-18AF-45E0-90F8-55FAE18D94D0Q45423826-8ABCAC32-7261-483E-A57B-5D762F55B1E2Q45719507-0A3577C0-B645-439A-91E6-4B892D8902FDQ45736523-450C9BBB-0BBE-4C99-BBC3-6A7F307C40B0Q45941425-44EFB462-A3BC-4F91-BDF7-56F22609FFAAQ46419370-C4A7E841-FD69-49E4-9D2E-5E7E9322792EQ46670668-783513FE-7A21-4642-A4EB-7A8A6D7EE439Q46702705-EF7F83A4-85A0-43AB-8050-48A56027401CQ46760610-92DE543F-6C28-4479-88C6-ECADCA5AAA16Q47738072-8D39CB96-00DF-4FA0-803B-40710D642E7FQ48002031-81C2BB72-42BB-49CA-BD9F-A44E7D45563AQ48616512-FC22847B-651C-493D-98FD-E19582FE774BQ50550145-B231CD38-49E5-4385-ABAA-91D111E8A9EC
P50
description
onderzoeker
@nl
researcher ORCID: 0000-0001-6699-7980
@en
name
Maurizio Pompili
@ast
Maurizio Pompili
@en
Maurizio Pompili
@es
Maurizio Pompili
@nl
Maurizio Pompili
@sl
type
label
Maurizio Pompili
@ast
Maurizio Pompili
@en
Maurizio Pompili
@es
Maurizio Pompili
@nl
Maurizio Pompili
@sl
prefLabel
Maurizio Pompili
@ast
Maurizio Pompili
@en
Maurizio Pompili
@es
Maurizio Pompili
@nl
Maurizio Pompili
@sl
P106
P1153
55513183000
P21
P31
P496
0000-0001-6699-7980